In the video below, Dr. Juliane Walz discusses a new clinical trial that is now open to patient enrollment at The University Hospital Tübingen in Tübingen, Germany. This FusionVAC22_02 clinical trial is designed to test the safety and efficacy of a peptide vaccine to delay or prevent the recurrence of fibrolamellar carcinoma (FLC). The peptide vaccine, made from a short sequence of amino acids, is designed to induce a patient’s immune system to recognize the fusion protein that causes FLC. In the trial, the vaccine will be administered alone, without additional immunotherapy or any other systemic agent.

The study will be open to patients who are judged free of cancer by radiological scans after surgery or other treatments. Patients must have a confirmed diagnosis of FLC or other cancer with the DNAJB1-PRKACA fusion transcript. Initially, the trial will only be open to patients 18 years old or older. After 6 adult patients have been enrolled, the study will open to patients age 12 and older.

The Fibrolamellar Cancer Foundation is providing the funding necessary to support this trial. For more information about this new study, please visit clinicaltrials.gov (NCT06789198) or the trial’s information page at The University Hospital (FL-HCC – Cancer Vaccine Study | Universitätsklinikum Tübingen).